Lyell Immunopharma, Inc. (LYEL)
Nasdaq: LYEL · Pharmaceutical Preparations · South San Francisco, CA · filing with the SEC since 2020
Who owns Lyell Immunopharma, Inc.
As filed with the SECHolders of 5% or more
5
ARCH Venture Fund IX, L.P. holds 13.9% of Common Stock par value $0.0001 per share, as its SCHEDULE 13G/A filed May 15, 2026 says.
Directors and officers
17
report now, of 23 people on the record since 2021. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
ARCH Venture Fund IX, L.P.
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock par value $0.0001 per share · 13% in Nov 14, 2025
Innovative Cellular Therapeutics Holdings Limited
SCHEDULE 13G/A · filed Jun 18, 2026 · Common Stock, par value $0.0001 · 9.8% in Nov 13, 2025
Euler Fund, L.P.
SCHEDULE 13G · filed Apr 21, 2026 · Common Stock
Explore Investments LLC
SCHEDULE 13G/A · filed May 8, 2026 · Common Stock, par value $0.0001 per share · 5.4% in Aug 19, 2025
Gates Frontier, LLC
SCHEDULE 13G · filed Aug 1, 2025 · Common Stock, $0.0001 par value per share
Blackrock, Inc.
SCHEDULE 13G/A · filed Feb 5, 2025 · Common Stock · reported falling below 5%
MWG Caph Ltd
SCHEDULE 13G/A · filed May 11, 2026 · Common Stock, $0.0001 par value per share · reported falling below 5%
Newton (PTC) Limited
SCHEDULE 13G/A · filed Nov 12, 2025 · Common Stock, $0.0001 par value per share · reported falling below 5%
James B. Tananbaum
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.0001 · reported falling below 5%, from 7.6% in Nov 14, 2025
What LYEL reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
ICT License Acquisition
A company bought · asset acquisition · owns, named in the 10-K filed Mar 12, 2026
ImmPACT Bio USA Inc.
A company bought · asset acquisition · owns, named in the 10-K filed Mar 12, 2026
Insider tradesForm 4
27sales
0purchases
0sales on a scheduled plan
6people selling
$600,000sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 12, 2025 to Nov 12, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 12, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window11 of 38 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Seely Lynn | President and CEO | 6 | $400,000 | 0 | 0 | $0 |
| Hill Stephen J. | Chief Operating Officer | 6 | $100,000 | 0 | 0 | $0 |
| Lee Gary K. | Chief Scientific Officer | 6 | $100,000 | 0 | 0 | $0 |
| Bulis Veronica Sanchez | VP, Corporate Controller | 6 | $100,000 | 0 | 0 | $0 |
| Arch Venture Fund Xiii, L.P. | 10% owner | 0 | $0 | 0 | 1 | $25.0M |
| Arch Venture Partners Ix Overage, L.P. | 10% owner | 0 | $0 | 0 | 1 | $12.5M |
| Arch Venture Partners Ix, LLC | 10% owner | 0 | $0 | 0 | 1 | $25.0M |
| Berns Paul L | 10% owner | 0 | $0 | 0 | 1 | $12.5M |
| Aguirre Jarrad Mattieu | Chief Medical Officer | 1 | $0 | 0 | 0 | $0 |
| Shook David | Chief Medical Officer | 2 | $0 | 0 | 0 | $0 |
| Innovative Cellular Therapeutics Holdings Ltd | 10% owner | 2 | $0 | 2 | 0 | $0 |